Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Nordic Nanovector
Nordic Nanovector
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
Nordic Nanovector to explore strategic options
Nordic Nanovector announces that its Board of Directors has appointed Carnegie Investment Bank to explore strategic options available to the company
Finance
Nordic Nanovector appoints Peter Braun CEO
In addition to his experience at Roche, Braun has also held roles at an artificial intelligence (AI)-driven life sciences start-up and as strategy consultant to emerging healthcare companies
Regulatory
Nordic Nanovector appoints Dr Reza Safaei as head of Medical Affairs
Nordic Nanovector appoints Lisa Rojkjaer, MD as Chief Medical Officer
Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team.
Ingredients
Nordic Nanovector and Heidelberg Pharma collaborate to develop novel ADCs targeting leukaemias
Leukaemias are orphan diseases with a significant unmet medical need, applicable indications representing a growing market worth more than $5 billion by 2020
Ingredients
Nordic Nanovector and LegoChem Biosciences collaborate to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth more than $5 billion by 2024
Regulatory
Betalutin publications highlight benefits of predosing regimen
Lilotomab predosing of NHL patients before Betalutin therapy lowers haematological toxicity with no reduction in the tumour absorbed radiation dose
Subscribe now